Literature DB >> 2801554

Quantitative comparison of thallium-201 scintigraphy after exercise and dipyridamole in coronary artery disease.

S K Varma1, D D Watson, G A Beller.   

Abstract

Data comparing myocardial thallium-201 imaging after exercise and intravenous dipyridamole infusion in the same patients are scarce. Accordingly, this study is a segment-by-segment quantitative analysis of regional uptake and washout of thallium-201 after dipyridamole (0.56 mg/kg) and symptom-limited exercise testing in 21 patients (ages 58 +/- 9.2 years) with chest pain studied 2.5 +/- 1.0 weeks apart. Thallium-201 activity in 9 myocardial segments was measured in initial and delayed anterior and 45 degree left anterior oblique views, producing 184 pairs of segments in the distribution of 63 coronary supply regions for direct comparison. The number of segments with normal thallium-201 uptake and the number of numerically significant defects were similar with exercise and dipyridamole (76 vs 73%, 24 vs 27%, respectively, difference not significant). A slightly higher proportion of redistribution defects was found after dipyridamole infusion compared to exercise (17 vs 10%, p less than 0.05). Agreement between 87% (165 of 189) of segment pairs was found when each was classified as either normal or abnormal. Although 24 of 189 segments were discordant, agreement was observed in 92% (61 of 63) of coronary supply regions determined to be normal (41 of 41) or abnormal (20 of 22). In 15 patients who underwent cardiac catheterization, exercise and dipyridamole-thallium-201 scintigraphy detected 61% (16 of 26) vs 61% (16 of 26) of stenoses greater than 50% (difference not significant) and 100% (19 of 19) vs 100% (19 of 19) (difference not significant) normal vessels, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2801554     DOI: 10.1016/0002-9149(89)90834-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  Pharmacologic stress myocardial perfusion imaging: a practical approach.

Authors:  Michael I Miyamoto; Sharon L Vernotico; Haresh Majmundar; Gregory S Thomas
Journal:  J Nucl Cardiol       Date:  2007-04       Impact factor: 5.952

2.  Pharmacological stress: a useful exercise?

Authors:  E E van der Wall
Journal:  Neth Heart J       Date:  2003-02       Impact factor: 2.380

3.  Improved coronary disease detection with quantitative attenuation-corrected Tl-201 images.

Authors:  Mathew Shotwell; Balkrishna M Singh; Charlotte Fortman; Brian D Bauman; Jennifer Lukes; Myron C Gerson
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

Review 4.  Do we still need dipyridamole?

Authors:  C R Gibbs; G Y Lip
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 5.  Myocardial perfusion imaging: clinical experience and recent progress in radionuclide scintigraphy and magnetic resonance imaging.

Authors:  J T Keijer; J J Bax; A C van Rossum; F C Visser; C A Visser
Journal:  Int J Card Imaging       Date:  1997-10

6.  Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study.

Authors:  Furqan H Tejani; Randall C Thompson; Ami E Iskandrian; Bruce E McNutt; Billy Franks
Journal:  J Nucl Cardiol       Date:  2010-11-17       Impact factor: 5.952

7.  Comparison of long-term mortality risk following normal exercise vs adenosine myocardial perfusion SPECT.

Authors:  Alan Rozanski; Heidi Gransar; Sean W Hayes; John D Friedman; Rory Hachamovitch; Daniel S Berman
Journal:  J Nucl Cardiol       Date:  2010-11-13       Impact factor: 5.952

8.  Higher events rate in patients with a normal gated myocardial perfusion imaging with dipyridamole than exercise: "Run for reliability".

Authors:  Nosheen Fatima; Maseeh Uz Zaman; Mohd Ishaq; S Zahed Rasheed; Dad J Baloch; Asif Wali; Javeria Bano; Kawish Rehman
Journal:  Indian J Nucl Med       Date:  2012-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.